James R. Kasinger - Oct 13, 2024 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
General Counsel and Secretary
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Oct 13, 2024
Transactions value $
-$50,399
Form type
4
Date filed
10/15/2024, 06:00 PM
Previous filing
Mar 22, 2024
Next filing
Oct 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +2.11K +3.43% 63.7K Oct 13, 2024 Direct F1, F2
transaction CRSP Common Shares Sale -$50.4K -1.09K -1.71% $46.28 62.6K Oct 14, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -2.11K -33.33% 4.23K Oct 13, 2024 Common Shares 2.11K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 Includes 399 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
F3 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F4 This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.